Arcadia Biosciences director granted 23K options

A director of Arcadia Biosciences received 23,000 stock options at a $0.46 exercise price, vesting in full by the earlier of September 10, 2027 or the next annual meeting.

Rhea-AI Filing Summary

Arcadia Biosciences, Inc. (RKDA) reported that director Kevin Comcowich received a grant of 23,000 stock options on September 10, 2026, with an exercise price of $0.46 per share and an expiration date of September 10, 2036. These options vest 100% on the earlier of September 10, 2027 or the company’s next Annual Meeting of Stockholders, subject to his continued service, bringing his reported outstanding option holdings to 54,042 options. No Rule 10b5-1 trading plan is reported for this award.

Insider Trade Summary

Grant/Award: 23,000 shares

Grant/Award 1 txn

Insider Comcowich Kevin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	23,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 54,042 contracts (Direct)

Footnotes (1)

1. F1. The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.

Key Figures

Stock options granted: 23,000 options Exercise price: $0.46 per share Options outstanding after grant: 54,042 options +2 more

5 metrics

Stock options granted 23,000 options Grant to director Kevin Comcowich on September 10, 2026

Exercise price $0.46 per share Exercise price for the 23,000 newly granted stock options

Options outstanding after grant 54,042 options Total reported option holdings for Kevin Comcowich following the grant

Expiration date September 10, 2036 Expiration date for the 23,000 newly granted options

Vesting date trigger September 10, 2027 or next annual meeting Earlier of the two dates when the options become 100% vested and exercisable, subject to continued service

Key Terms

vested and exercisable, Annual Meeting of Stockholders, continued service

3 terms

vested and exercisable financial

"The Option will become 100% vested and exercisable on the earlier to occur"

Annual Meeting of Stockholders regulatory

"or (ii) the date of the Issuer's next Annual Meeting of Stockholders"

continued service financial

"the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arcadia Biosciences (RKDA) report for Kevin Comcowich?

Arcadia Biosciences reported that director Kevin Comcowich received a grant of 23,000 stock options on September 10, 2026, with an exercise price of $0.46 per share and an expiration date of September 10, 2036, as part of his director compensation.

What is the exercise price of the new stock options granted at RKDA?

The newly granted stock options to director Kevin Comcowich have an exercise price of $0.46 per share. The options relate to Arcadia Biosciences common stock and expire on September 10, 2036.

When do the newly granted RKDA options to Kevin Comcowich vest?

The options will become 100% vested and exercisable on the earlier of September 10, 2027 or the date of Arcadia Biosciences’ next Annual Meeting of Stockholders, subject to Kevin Comcowich’s continued service.

How many Arcadia Biosciences options does Kevin Comcowich hold after this grant?

After the September 10, 2026 grant, Kevin Comcowich is reported to hold 54,042 stock options for Arcadia Biosciences common stock, including the newly granted 23,000 options.

Are the new RKDA option grants to Kevin Comcowich under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with the September 10, 2026 stock option grant to director Kevin Comcowich.

What is the expiration date of Kevin Comcowich’s new Arcadia Biosciences options?

The newly granted stock options to Kevin Comcowich expire on September 10, 2036, giving him a ten-year term to exercise the options once they become vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:03 PM Accepted by SEC EDGAR 09/14/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Comcowich Kevin

(Last) (First) (Middle)

C/O ARCADIA BIOSCIENCES, INC.

5956 SHERRY LANE, SUITE 2000

(Street)

DALLAS TEXAS 75225

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcadia Biosciences, Inc. [ RKDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.46	09/10/2026		A		23,000		(1)	09/10/2036	Common Stock	23,000	$0	54,042	D

Explanation of Responses:

1. The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.

	Kevin Comcowich, by Attorney-in-fact, Solaeta Chan	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)